Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuto Ito

Showing results (11-20 of 117) with videos related to

Pageof 12
Sort By:
The Prostate|March 1, 2002
Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communitiesYutaka Kubota, Kazuto Ito, Kyoichi Imai, et al.
International Journal of Clinical Oncology|August 20, 2014
Next-generation prostate-specific antigen test: precursor form of prostate-specific antigenKazuto Ito, Yuji Fujizuka, Kiyohide Ishikura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 13, 2008
Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in JapanKazuto Ito, Yoshiyuki Kakehi, Seiji Naito, et al.
Hinyokika Kiyo. Acta Urologica Japonica|October 17, 2012
[Septic shock following flexible transurethral lithotripsy showing favourable response after multidisciplinary treatment mainly composed of recombinant thrombomodulin : a case report]Haruo Kato, Yasuhiro Shibata, Tomomi Suzuki, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2013
The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohortHiromi Hirama, Mikio Sugimoto, Kazuto Ito, et al.
European Urology|December 12, 2003
Diagnostic significance of PSA density adjusted by transition zone volume in males with PSA levels between 2 and 4ng/mlMasaru Ohi, Kazuto Ito, Kazuhiro Suzuki, et al.
The Journal of Urology|January 10, 2004
The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or lessKazuto Ito, Takumi Yamamoto, Kazuhiro Suzuki, et al.
Journal of Clinical Laboratory Analysis|March 1, 2014
Stability of [-2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditionsTsukasa Igawa, Kosuke Takehara, Toru Onita, et al.
Urology|March 18, 2008
Prostate-specific antigen kinetics in screen-detected prostate cancer in JapanHiroyuki Takechi, Kazuto Ito, Takumi Yamamoto, et al.
Hinyokika Kiyo. Acta Urologica Japonica|March 5, 2003
[Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]Kenkichi Koiso, Hidetoshi Yamanaka, Kazuto Ito, et al.
Pageof 12

Showing results (11-20 of 117) with videos related to

Sort By:
Pageof 12
The Prostate|March 1, 2002
Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communitiesYutaka Kubota, Kazuto Ito, Kyoichi Imai, et al.
International Journal of Clinical Oncology|August 20, 2014
Next-generation prostate-specific antigen test: precursor form of prostate-specific antigenKazuto Ito, Yuji Fujizuka, Kiyohide Ishikura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 13, 2008
Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in JapanKazuto Ito, Yoshiyuki Kakehi, Seiji Naito, et al.
Hinyokika Kiyo. Acta Urologica Japonica|October 17, 2012
[Septic shock following flexible transurethral lithotripsy showing favourable response after multidisciplinary treatment mainly composed of recombinant thrombomodulin : a case report]Haruo Kato, Yasuhiro Shibata, Tomomi Suzuki, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2013
The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohortHiromi Hirama, Mikio Sugimoto, Kazuto Ito, et al.
European Urology|December 12, 2003
Diagnostic significance of PSA density adjusted by transition zone volume in males with PSA levels between 2 and 4ng/mlMasaru Ohi, Kazuto Ito, Kazuhiro Suzuki, et al.
The Journal of Urology|January 10, 2004
The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or lessKazuto Ito, Takumi Yamamoto, Kazuhiro Suzuki, et al.
Journal of Clinical Laboratory Analysis|March 1, 2014
Stability of [-2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditionsTsukasa Igawa, Kosuke Takehara, Toru Onita, et al.
Urology|March 18, 2008
Prostate-specific antigen kinetics in screen-detected prostate cancer in JapanHiroyuki Takechi, Kazuto Ito, Takumi Yamamoto, et al.
Hinyokika Kiyo. Acta Urologica Japonica|March 5, 2003
[Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]Kenkichi Koiso, Hidetoshi Yamanaka, Kazuto Ito, et al.
Pageof 12